Tumor-specific single-gene or targeted analyses may be considered reasonable and necessary for the listed indications:
BCR-ABL1 kinase domain analysis: CML or Philadelphia-positive ALL AND inadequate initial response to TKI therapy OR loss of response OR progression to accelerated/blast phase OR relapsed/refractory disease.
Tumor-specific BCR-ABL1 testing includes kinase domain analysis and qualitative/quantitative assays as clinically indicated.
BCR-ABL1 FISH/qual/quant: Suspected MPN OR diagnostic workup for ALL, AML, CML, or lymphoblastic leukemia OR MRD/monitoring for ALL, AML, CML when a quantitative test is used and the provider is considering discontinuation of or has discontinued TKI therapy.
Includes FISH, qualitative, and quantitative testing as appropriate.
CALR variant analysis: Suspected MPN OR suspected MDS.
Per NCCN recommendations for initial MPN/MDS workup.
CEBPA variant analysis: Evaluation for AML.
Used for prognostication and treatment planning in AML.
FLT3 variant analysis: Suspected or confirmed AML OR diagnosis of ALL, MDS, or MPN.
FLT3 testing recommended for prognostic stratification in AML and ALL.
IDH1/IDH2 variant analysis: Diagnosis of AML.
IDH1/2 testing indicated in AML evaluation.
IGHV somatic hypermutation analysis: Workup for or diagnosis of CLL, SLL, primary cutaneous B-cell lymphoma, or other B-cell lymphomas.
IGHV mutation status informs prognosis and therapy selection in CLL/SLL.
JAK2 variant analysis: Suspected MPN OR ALL OR suspected MDS.
JAK2 testing is part of MPN/MDS evaluation and may be included in panels.
KIT variant analysis: Evaluation for systemic mastocytosis OR diagnosis of AML.
KIT testing indicated for mastocytosis and some AML cases.
MPL variant analysis: Suspected MPN OR suspected MDS.
MPL testing included in MPN-directed panels.
NPM1 variant analysis: Evaluation for AML.
NPM1 testing recommended in AML workup.
NTRK fusion analysis (FISH/IHC): Diagnosis of acute lymphoblastic leukemia (ALL) at any stage for risk stratification.
NTRK fusion analysis may be performed by FISH or IHC per guideline guidance.
TP53 variant analysis: Diagnosis of AML, CLL, or SLL OR diagnostic workup for mantle cell lymphoma or multiple myeloma.
TP53 sequencing is recommended for prognostic and therapeutic decision-making.